Evidence map›Paper›PMID 42894078›Full record

ReviewJournal of cancer research and clinical oncology2026

Nucleotide excision repair in tumor response to DNA-damaging anticancer therapies: a comprehensive review.

Bartosz Maćkowiak, Kamila Ostrowska, Julia Kozikowska, Katarzyna Kulcenty, Wojciech Golusiński, Wiktoria Suchorska

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bartosz MaćkowiakRadiobiology Laboratory, Greater Poland Cancer Centre, Garbary 15 Street, Poznan, 61-866, Poland. barmackowiak@gmail.com.ORCID https://orcid.org/0009-0009-6786-5707
Kamila OstrowskaRadiobiology Laboratory, Greater Poland Cancer Centre, Garbary 15 Street, Poznan, 61-866, Poland.
Julia KozikowskaRadiobiology Laboratory, Greater Poland Cancer Centre, Garbary 15 Street, Poznan, 61-866, Poland.
Katarzyna KulcentyRadiobiology Laboratory, Greater Poland Cancer Centre, Garbary 15 Street, Poznan, 61-866, Poland.
Wojciech GolusińskiDepartment of Head and Neck Surgery, Poznan University of Medical Sciences, Garbary 15 Street, Poznan, 61-866, Poland.
Wiktoria SuchorskaRadiobiology Laboratory, Greater Poland Cancer Centre, Garbary 15 Street, Poznan, 61-866, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleotide excision repair (NER) is a critical DNA repair pathway responsible for removing bulky, helix-distorting DNA lesions, including ultraviolet radiation-induced photoproducts and platinum drug-DNA adducts. This review provides a comprehensive overview of current understanding of NER in cancer, with particular emphasis on its role in therapeutic response. We discuss the molecular mechanisms of DNA repair in cancer, the significance of NER in platinum-based therapies, results from in vitro studies across various cancer types, findings from patient-based studies, and outcomes from clinical trials. Special attention is given to ERCC1, ERCC2/XPD, XPA, and XPC molecules as potential biomarkers of treatment response and therapeutic targets, and incorporating the most recent discoveries regarding NER inhibitors, mutational signatures, and synthetic lethality-based approaches.

Indexed as

Antineoplastic AgentsDNA DamageDNA RepairExcision RepairNeoplasmsAnimalsDNA-Binding ProteinsEndonucleasesHumansAntineoplastic AgentsDNA-Binding ProteinsEndonucleasesERCC1 protein, humanBiomarkersCancer therapyDNA damage repairNucleotide excision repair

Identifiers

PMID42894078
PMCPMC13677657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.